Project information | Lung cancer (non-small cell) - afatinib [ID357] | Guidance

Afatinib for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib

Please note that following on from information provided to NICE by the company in July 2011, the appraisal of Afatinib for the treatment of locally advanced or metastatic non small cell lung cancer was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

Status	Discontinued
Decision	Selected
Process	TA
Referral date	01 July 2010
Topic area	Cancer Respiratory
Description	Scoped within Batch 12

Provisional Schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC

Project Team

Communications manager:	TBC
Executive Lead:	TBC
Project manager:	Jeremy Powell
Technical Lead:	TBC

Timeline

Key events during the development of the guidance:

Date	Update
23 January 2023	Discontinued. Please note that following on from information provided to NICE by the company in July 2011, the appraisal of Afatinib for the treatment of locally advanced or metastatic non small cell lung cancer was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
28 July 2011	As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of afatinib within its licensed indication for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib as part of our 22^nd wave work programme. The Institute has been informed by the manufacturer that it is not expecting to receive a separate marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being. This indication is now planned to be part of the regulatory submission of afatinib for NSCLC, locally advanced and/or metastatic with EGFR mutation positive.
3 December 2010	Following on from information received from the manufacturer, dates for this appraisal will be confirmed once regulatory approval timelines are established.

Date

Update

23 January 2023

Discontinued. Please note that following on from information provided to NICE by the company in July 2011, the appraisal of Afatinib for the treatment of locally advanced or metastatic non small cell lung cancer was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

28 July 2011

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of afatinib within its licensed indication for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib as part of our 22^nd wave work programme.

The Institute has been informed by the manufacturer that it is not expecting to receive a separate marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

This indication is now planned to be part of the regulatory submission of afatinib for NSCLC, locally advanced and/or metastatic with EGFR mutation positive.

3 December 2010

Following on from information received from the manufacturer, dates for this appraisal will be confirmed once regulatory approval timelines are established.

For further information on our processes and methods, please see our CHTE processes and methods manual